Insilico Medicine presented its latest advancements in applying artificial intelligence to longevity science and therapeutic discovery at the Bio Asia Taiwan 2026 conference. The company highlighted how AI-driven platforms are being utilized to redefine traditional drug development paradigms and accelerate the identification of novel therapeutic targets. By integrating large-scale biological data with machine learning models, Insilico aims to streamline the path from discovery to clinical application. This development underscores the growing intersection between computational intelligence and biotechnology. How significant will AI-driven drug discovery be in extending human healthspan over the next decade?
Source: https://www.geneonline.com/bio-asia-taiwan-2026-ai-meets-longevity-science-july-007-report/
